tradingkey.logo

Shionogi & Co Ltd - Planned Acquisition Of Global Rights To Tanabe Pharma's RADICAVA ORS And IV RADIC

ReutersDec 22, 2025 10:06 AM

- Shionogi & Co Ltd 4507.T:

  • SHIONOGI EXPANDS RARE DISEASE PRESENCE WITH PLANNED ACQUISITION OF GLOBAL RIGHTS TO TANABE PHARMA CORPORATION'S RADICAVA ORS (EDARAVONE) AND IV RADIC

  • TO PAY LUMP SUM OF $2.5 BILLION TO TANABE PHARMA UPON COMPLETION OF PROCEDURES

  • MAY PAY A ROYALTY ON FUTURE SALES, SUBJECT TO CERTAIN CONDITIONS

  • TRANSACTION EXPECTED TO BE IMMEDIATELY ACCRETIVE IN FY26, ADDING APPROXIMATELY USD 700 MILLION IN ANNUAL GLOBAL SALES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI